Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Receivables (2020 - 2025)

Tarsus Pharmaceuticals has reported Change in Receivables over the past 6 years, most recently at $37.9 million for Q4 2025.

  • Quarterly results put Change in Receivables at $37.9 million for Q4 2025, up 115.21% from a year ago — trailing twelve months through Dec 2025 was $38.3 million (up 27.07% YoY), and the annual figure for FY2025 was $38.3 million, up 27.07%.
  • Change in Receivables for Q4 2025 was $37.9 million at Tarsus Pharmaceuticals, up from -$190000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for TARS hit a ceiling of $37.9 million in Q4 2025 and a floor of -$15.1 million in Q2 2025.
  • Median Change in Receivables over the past 5 years was -$46000.0 (2021), compared with a mean of $3.5 million.
  • Biggest five-year swings in Change in Receivables: soared 21683.33% in 2022 and later crashed 18717.65% in 2023.
  • Tarsus Pharmaceuticals' Change in Receivables stood at -$46000.0 in 2021, then tumbled by 8382.61% to -$3.9 million in 2022, then plummeted by 101.23% to -$7.9 million in 2023, then skyrocketed by 324.16% to $17.6 million in 2024, then skyrocketed by 115.21% to $37.9 million in 2025.
  • The last three reported values for Change in Receivables were $37.9 million (Q4 2025), -$190000.0 (Q3 2025), and -$15.1 million (Q2 2025) per Business Quant data.